Lung Cancer Considered

At the time it was published in the New England Journal of Medicine in 2002, ECOG 1594 was the first study to compare whether any of the three chemotherapy regimens used at the time was superior to cisplatin and paclitaxel in patients with advanced non–small-cell lung cancer. In this episode of Lung Cancer Considered, hosts Dr. Stephen Liu and Dr. Narjust Florez interview the ECOG 1594 clinical trial investigators (Dr. Frances Shepherd, Dr. Alan Sandler, Dr. Chandra Belani, Dr. Corey Langer and Dr. Joan Schiller) to learn just how important, and controversial, this study was.

Lung cancer research is often centered at large, urban academic medical centers. But what research and treatment options are available for those patients with lung cancer who live in rural areas? In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses the state of rural lung cancer care and research with Dr. Debora Bruno, a thoracic medical oncologist at Case Western in Cleveland. Dr. Bruno worked in rural Nebraska for three years after the completion of her fellowship where she was able to help establish a multi-disciplinary clinic for patients with lung cancer. Also participating in the podcast is Dr. Gabrielle Rocque, associate professor of medicine at the O’Neal Comprehensive Cancer Center at the University of Alabama. Dr. Rocque has a strong interest in the interface between community oncology practices and academia.

In this special edition of Lung Cancer Considered, three esteemed oncologists and lung cancer experts explore the issues facing the medical profession in China.

Host Dr. Chunxia Su, Professor of Oncology at Tongji University and Deputy Director of Medical Oncology at Shanghai Pulmonary Hospital, welcomes guests Prof. Shun Lu, Director of the Chinese Lung Cancer Association, Board Member of the Chinese Society of Clinical Oncology, and Director of the Shanghai Lung Cancer Center; and Prof. Caicun Zhou, Chief Physician and Director of Medical Oncology at Tongji University in Shanghai Pulmonary Hospital and current member of the IASLC Board of Directors.

In keeping with its mission to cover lung cancer from a global perspective, this episode of Lung Cancer Considered focuses on lung cancer in Japan. Host Dr. Misako Nagasaka, a Thoracic Medical Oncologist from the University of California Irvine leads a Japanese-language discussion about lung cancer in Japan with respected oncologists Dr. Tetsuya Mitsudomi and Dr. Takashi Seto. Dr. Seto is a Thoracic Medical Oncologist from the National Kyushu Cancer Center in Fukuoka, Japan and Dr. Tetsuya Mitsudomi is a Professor in the Division of Thoracic Surgery at Kindai University in Osaka-Sayama, Japan. He is also the immediate past IASLC president.

Over the past few years, the use of liquid biopsy has improved the ability to detect biomarkers for non-small cell lung cancer. In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the current state of liquid biopsies with Dr. David Gandara, Professor of Medicine and Director of Thoracic Oncology at the University of California, Davis; Dr. Charu Aggarwal, the Leslye M. Heisler Associate Professor for Lung Cancer Excellence at the University of Pennsylvania; and Dr. Christian Rolfo, Professor of Medicine at Mount Sinai in New York City and the Associate Director for Clinical Research in the Center for Thoracic Oncology at the Tisch Cancer Institute.

In this episode of Lung Cancer Considered, host Dr. Narjust Florez talks about the critical role interventional pulmonologists play on the cancer care team. Joining the discussion are Dr. Daniel Sterman, the Thomas and Suzanne Murphy Professor of Pulmonary and Critical Care Medicine at the New York University Grossman School of Medicine and Dr. Rebecca Krochmal, Assistant Professor of Medicine in the Division of Pulmonary, Critical Care and Sleep Medicine at the Georgetown University School of Medicine.

Did you miss ESMO this year? Listen to Lung Cancer Considered host and thoracic oncologist Dr. Narjust Florez discuss the key highlights involving science and notable abstracts at the meeting with Dr. Joshua Reuss, Thoracic Medical Oncologist and Assistant Professor of Medicine at Georgetown and Dr. Giannis Mountzios, Director of the Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center in Athens, Greece.

The role of the pathologist in lung cancer treatment has dramatically evolved as our understanding of lung cancer biology has advanced. Lung Cancer Considered host Dr. Stephen Liu discusses that evolution with renowned lung cancer pathologists Dr. Dara Aisner from the University of Colorado and Dr. Ignacio Wistuba from MD Anderson Cancer Center.

Dr. Wistuba is a Professor in the Department of Thoracic and Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston. He is the Head of the Division of Pathology and Lab Medicine and an expert in translational pathology.

Dr. Aisner is an Associate Professor in the Department of Pathology at the University of Colorado in Aurora, CO. She has expertise in Anatomic as well as Molecular Genetic Pathology and is the Medical Director of the Colorado Molecular Correlates Laboratory.

Lung Cancer Considered Host Dr. Stephen Liu leads a recap of the recently completed IASLC 2022 North America Conference on Lung Cancer featuring guests Dr. Jessica Donington, Professor and Chief Thoracic Surgery University of Chicago; Dr.Jyoti Patel, Thoracic Medical Oncology, Robert H Lurie Comprehensive Cancer Center, Northwestern University and Dr. Shruti Patel, Oncology Fellow at Stanford School of Medicine.

Career transitions are normal in academic oncology, oncology practice, and industry and today's oncologists go through a number of 'job' interviews during their post-graduate life and early career. In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses how to find or transition to that new job in thoracic oncology. Joining the discussion are three lung cancer researchers:

Dr. Mark Awad, clinical director of the Thoracic Oncology Group at Dana Farber Cancer Institute, assistant professor of Medicine at Harvard Medical School and a leading researcher in KRAS-mutant NSCLC.

Dr. Ana Velazquez, instructor of medicine and thoracic medical oncologist at UCSF and a postdoctoral fellow at the National Clinical Scholars Program. Dr. Velazquez is completing her training and searching for her faculty position.

Dr. Jyoti Patel, associate vice for clinical research, a thoracic medical oncologist, and professor of medicine at Northwestern University in Chicago. Dr. Patel is a leader in thoracic oncology, focusing her efforts on the development and evaluation of novel molecular markers and therapeutics for patients with non-small cell lung cancer.